About zanubrutin ib
Bruton tyrosine kinase inhibitor
Used for
- Treats certain blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia.
- May treat marginal zone lymphoma and relapsed follicular lymphoma in certain settings.
Usual adult dose
Usually 160 mg twice daily or 320 mg once daily; dose may vary by condition and treatment plan.
Common side effects
- Low blood-cell counts, including neutropenia and low platelets
- Bruising or bleeding
- Infections
- Diarrhea, rash, or muscle and joint pain
Important warnings
- Can cause serious or fatal bleeding; risk increases with blood thinners.
- May cause serious infections, low blood counts, or abnormal heart rhythms.
- Rarely causes severe liver injury; liver tests may be monitored.
- Can harm an unborn baby; effective contraception is recommended during treatment.
Pregnancy
May cause fetal harm. Avoid use during pregnancy; contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase drug levels; dose adjustment may be needed.
- CYP3A inducers can reduce drug levels and effectiveness.
- Blood thinners and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.